Passage Bio Stock Performance
| PASG Stock | USD 0.33 0.02 5.71% |
On a scale of 0 to 100, Passage Bio holds a performance score of 2. The company holds a Beta of 1.9, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Passage Bio will likely underperform. Please check Passage Bio's kurtosis, as well as the relationship between the day median price and period momentum indicator , to make a quick decision on whether Passage Bio's historical price patterns will revert.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Passage Bio are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak basic indicators, Passage Bio reported solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Disposition of 10326 shares by Orbimed Advisors Llc of Passage Bio at 0.38 subject to Rule 16b-3 | 04/15/2025 |
2 | Disposition of 61638 shares by Orbimed Advisors Llc of Passage Bio at 0.33 subject to Rule 16b-3 | 04/16/2025 |
3 | Disposition of 77090 shares by Orbimed Advisors Llc of Passage Bio at 0.33 subject to Rule 16b-3 | 04/17/2025 |
4 | Disposition of 78049 shares by Orbimed Advisors Llc of Passage Bio at 0.34 subject to Rule 16b-3 | 04/22/2025 |
5 | Disposition of 89328 shares by Orbimed Advisors Llc of Passage Bio at 0.34 subject to Rule 16b-3 | 04/23/2025 |
6 | Disposition of 68195 shares by Orbimed Advisors Llc of Passage Bio at 0.32 subject to Rule 16b-3 | 04/24/2025 |
7 | Passage Bio Advances Phase 12 Trial for PBFT02, Eyes Future Milestones PASG Stock News | 05/13/2025 |
8 | Guggenheim Adjusts Price Target for Passage Bio PASG Stock News | 05/20/2025 |
9 | Acquisition by Kassberg Thomas Richard of 143789 shares of Passage Bio at 0.3598 subject to Rule 16b-3 | 05/28/2025 |
10 | Passage Bio Announces Key Updates from PBFT02 Clinical Trial PASG Stock News | 06/23/2025 |
11 | Disposition of 231600 shares by Orbimed Advisors Llc of Passage Bio at 0.35 subject to Rule 16b-3 | 06/24/2025 |
12 | Disposition of 213257 shares by Orbimed Advisors Llc of Passage Bio at 0.33 subject to Rule 16b-3 | 06/26/2025 |
| Begin Period Cash Flow | 21.7 M |
Passage Bio Relative Risk vs. Return Landscape
If you would invest 35.00 in Passage Bio on March 31, 2025 and sell it today you would lose (2.00) from holding Passage Bio or give up 5.71% of portfolio value over 90 days. Passage Bio is currently generating 0.2074% in daily expected returns and assumes 8.0055% risk (volatility on return distribution) over the 90 days horizon. In different words, 71% of stocks are less volatile than Passage, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Passage Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Passage Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Passage Bio, and traders can use it to determine the average amount a Passage Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0259
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PASG | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 8.01 actual daily | 71 71% of assets are less volatile |
Expected Return
| 0.21 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Passage Bio is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Passage Bio by adding it to a well-diversified portfolio.
Passage Bio Fundamentals Growth
Passage Stock prices reflect investors' perceptions of the future prospects and financial health of Passage Bio, and Passage Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Passage Stock performance.
| Return On Equity | -0.84 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | (17.42 M) | ||||
| Shares Outstanding | 62.15 M | ||||
| Price To Book | 0.44 X | ||||
| EBITDA | (61.69 M) | ||||
| Net Income | (64.77 M) | ||||
| Cash And Equivalents | 239.25 M | ||||
| Cash Per Share | 4.39 X | ||||
| Total Debt | 25.48 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 9.23 X | ||||
| Book Value Per Share | 0.75 X | ||||
| Cash Flow From Operations | (47.96 M) | ||||
| Earnings Per Share | (1.02) X | ||||
| Market Capitalization | 20.58 M | ||||
| Total Asset | 102.41 M | ||||
| Retained Earnings | (659.24 M) | ||||
| Working Capital | 59.45 M | ||||
| Current Asset | 144.91 M | ||||
| Current Liabilities | 3.09 M | ||||
About Passage Bio Performance
By analyzing Passage Bio's fundamental ratios, stakeholders can gain valuable insights into Passage Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Passage Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Passage Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.63) | (0.66) | |
| Return On Capital Employed | (0.85) | (0.89) | |
| Return On Assets | (0.63) | (0.66) | |
| Return On Equity | (1.06) | (1.00) |
Things to note about Passage Bio performance evaluation
Checking the ongoing alerts about Passage Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Passage Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Passage Bio had very high historical volatility over the last 90 days | |
| Passage Bio has some characteristics of a very speculative penny stock | |
| Passage Bio has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (64.77 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Passage Bio currently holds about 239.25 M in cash with (47.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.39, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Passage Bio has a frail financial position based on the latest SEC disclosures | |
| Roughly 58.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 213257 shares by Orbimed Advisors Llc of Passage Bio at 0.33 subject to Rule 16b-3 |
- Analyzing Passage Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Passage Bio's stock is overvalued or undervalued compared to its peers.
- Examining Passage Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Passage Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Passage Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Passage Bio's stock. These opinions can provide insight into Passage Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Passage Stock analysis
When running Passage Bio's price analysis, check to measure Passage Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Passage Bio is operating at the current time. Most of Passage Bio's value examination focuses on studying past and present price action to predict the probability of Passage Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Passage Bio's price. Additionally, you may evaluate how the addition of Passage Bio to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |